HER 2 Testing Service

Written by Robert Storer on .

We perform over 2000 HER2 Immunohistochemistry and 800 FISH tests per year, on breast cancer cases, using FDA approved and validated assays ( Pathway 4B5 antibody from Roche/Ventana and PathVysion dual colour FISH probe from Abbott Molecular (both CE marked)
All testing is performed in accordance with National Guidelines.

References:

  • Bartlett JMS, Starczynski J et al. HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. J Clin Pathol 2011; 64: 649-653)
  • Woolff AC, Hammond EH et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor 2 Testing in Breast Cancer. J Clin Oncol 2007; 25 (1): 118-145
  • Walker RA, Bartlett JMS et al. HER2 testing in the UK: further update to recommendations. J Clin Pathol 2008; 61: 818-824
  • Ellis IO, Dowsett M et al. Recommendations for HER2 testing in the UK. J Clin Pathol 2000; 53: 890-2
  • Ellis IO, Bartlett J et al. Updated recommendations for HER2 testing in the UK. J Clin Pathol 2004; 57: 233-7)

We are a national reference centre laboratory for HER2 testing
We participate in national UKNEQAS scheme for HER2 testing
We are actively involved in monitoring and auditing all aspects of the HER2 service to best meet the need of our users.